Table 3.

Associations between estrogen metabolizing polymorphisms and breast cancer risk in the BBD cohort

		Cancer		No Cancer
	dbSNP rs#	(n = 91)		(n = 1347)		All Participants	Post-menopausal Only
		n	%	n	%	Age- Adjusted OR (95% CI)	Age- Adjusted OR (95% CI)
COMT Val158Met	4680
GG		16	17.6	272	20.2	1.00	1.00
GA		41	45.1	608	45.1	1.15 (0.63, 2.08)	0.89 (0.45, 1.77)
AA		24	26.4	371	27.5	1.10 (0.57, 2.11)	0.90 (0.43, 1.90)
GA/AA		65	71.4	979	72.7	1.13 (0.64, 1.98)	0.89 (0.47, 1.70)
Missing		10	11.0	96	7.1
CYP1A1 Ile462Val	1048943
AA		78	85.7	1233	91.5	1.00	1.00
AG		7	7.7	80	5.9	1.38 (0.62, 3.10)	1.30 (0.45, 3.74)
GG		1	1.1	5	0.4	3.33 (0.38, 28.99)	8.33 (0.74, 93.62)
p-for-trend						0.20	0.20
AG/GG		8	8.8	85	6.3	1.49 (0.70, 3.19)	1.56 (0.60, 4.08)
Missing		5	5.5	29	2.2
CYP1B1 Asn453Ser	1800440
AA		51	56.0	866	64.3	1.00	1.00
AG		31	34.1	358	26.6	1.45 (0.91, 2.31)	1.51 (0.87, 2.65)
GG		4	4.4	37	2.7	1.77 (0.61, 5.16)	2.44 (0.81, 7.36)
p-for-trend						0.08	0.05
AG/GG		35	38.5	395	29.3	1.48 (0.95, 2.32)	1.61 (0.94, 2.74)
Missing		5	5.5	86	6.4
CYP1B1 Arg48Gly	10012
CC		39	42.9	600	44.5	1.00	1.00
CG		33	36.3	460	34.1	1.10 (0.68, 1.78)	0.95 (0.53, 1.69)
GG		3	3.3	76	5.6	0.60 (0.18, 2.00)	0.25 (0.03, 1.88)
CG/GG		36	39.6	536	39.8	1.02 (0.65, 1.64)	0.84 (0.48, 1.50)
Missing		16	17.6	211	15.7
CYP1B1 Val432Leu	1056836
CC		25	27.5	365	27.1	1.00	1.00
CG		39	42.9	653	48.5	0.88 (0.53, 1.48)	1.04 (0.56, 1.98)
GG		17	18.7	270	20.0	0.93 (0.49, 1.76)	0.93 (0.41, 2.09)
CG/GG		56	61.5	923	68.5	0.90 (0.55, 1.46)	1.01 (0.56, 1.85)
Missing		10	11.0	59	4.4